(Q34974866)

5 August 2017

1 reference

title

Antioxidants as treatment for neurodegenerative disorders (English)

1 reference

5 August 2017

1 reference

Bernd Moosmann

1

1 reference

5 August 2017

Christian Behl

series ordinal

2

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

published in

1 reference

5 August 2017

volume

11

1 reference

5 August 2017

issue

10

1 reference

5 August 2017

page(s)

1407-1435

1 reference

Copernicus revisited: amyloid beta in Alzheimer's disease

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Oxidative stress and genetics in the pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Oxidative Stress and Motor Neurone Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Chemistry and biochemistry of oxidative stress in neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Biochemistry of neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Oxidation of cysteine-322 in the repeat domain of microtubule-associated protein tau controls the in vitro assembly of paired helical filaments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Acrolein is increased in Alzheimer's disease brain and is toxic to primary hippocampal cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Chronic systemic pesticide exposure reproduces features of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Extending functional life span

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Genetic analysis of ageing: role of oxidative damage and environmental stresses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

A hypothesis on the pathogenesis of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Strategies of antioxidant defense

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mitochondrial energy metabolism is regulated via nuclear-coded subunits of cytochrome c oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mitochondrial production of hydrogen peroxide regulation by nitric oxide and the role of ubisemiquinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mitochondrial dysfunction in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Excitotoxins in neuronal apoptosis and necrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Antioxidants, oxidative stress, and degenerative neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

N-t-butyl hydroxylamine, a hydrolysis product of alpha-phenyl-N-t-butyl nitrone, is more potent in delaying senescence in human lung fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

N-t-Butyl hydroxylamine is an antioxidant that reverses age-related changes in mitochondria in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Amyloid plaque core protein in Alzheimer disease and Down syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Intramembrane proteolysis by presenilins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Alzheimer's disease and oxidative stress: implications for novel therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Multiple antioxidants in the prevention and treatment of Alzheimer disease: analysis of biologic rationale

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Oxidative damage is the earliest event in Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

In vitro peroxidase oxidation induces stable dimers of beta-amyloid (1-42) through dityrosine bridge formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Accelerated accumulation of amyloid beta proteins on oxidatively damaged lipid membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Vitamin E protects nerve cells from amyloid beta protein toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

L-deprenyl in Alzheimer's disease: cognitive and behavioral effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Selegiline treatment and the extent of degenerative changes in brain tissue of patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

A 1-year controlled trial of acetyl-l-carnitine in early-onset AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Long-term acetyl-L-carnitine treatment in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Acetyl-L-carnitine physical-chemical, metabolic, and therapeutic properties: relevance for its mode of action in Alzheimer's disease and geriatric depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Protective effects of idebenone and alpha-tocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Idebenone protects hippocampal neurons against amyloid beta-peptide-induced neurotoxicity in rat primary cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Controlled trial of N-acetylcysteine for patients with probable Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Postmenopausal estrogen replacement therapy and risk of AD: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Hormone replacement therapy and reduced cognitive decline in older women: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Anti‐inflammatory agents as a therapeutic approach to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Phagocytes and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

An investigation into the neuroprotective properties of ibuprofen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The antioxidant neuroprotective effects of estrogens and phenolic compounds are independent from their estrogenic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The effects of hormone replacement therapy on lipid peroxidation and antioxidant status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Comparison of the antioxidant effects of equine estrogens, red wine components, vitamin E, and probucol on low-density lipoprotein oxidation in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Estrogen for Alzheimer's disease in women: randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Effects of estrogen on cognition, mood, and cerebral blood flow in AD: a controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

High-dose estradiol improves cognition for women with AD: results of a randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Anti-inflammatory drugs: a hope for Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

An assessment of the antioxidant and the antiamyloidogenic properties of melatonin: implications for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Melatonin acts as antioxidant and pro-oxidant in an organotypic slice culture model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The Ginkgo biloba extract (EGb 761) protects and rescues hippocampal cells against nitric oxide-induced toxicity: involvement of its flavonoid constituents and protein kinase C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The in vivo neuromodulatory effects of the herbal medicine ginkgo biloba

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Proof of efficacy of the ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Metal chelator decreases Alzheimer beta-amyloid plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Iron accumulation in Alzheimer disease is a source of redox-generated free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Intramuscular desferrioxamine in patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Hydrogen peroxide mediates amyloid beta protein toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

beta-Amyloid toxicity in organotypic hippocampal cultures: protection by EUK-8, a synthetic catalytic free radical scavenger

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

EUK-134, a synthetic superoxide dismutase and catalase mimetic, prevents oxidative stress and attenuates kainate-induced neuropathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Parkinson's disease. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Parkinson's disease. Second of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Parkinson disease in twins: an etiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Risk factors for parkinson's disease: the leisure world cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Current evidence for neuroprotective effects of nicotine and caffeine against Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Risk factors of Parkinson's disease in Indian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Neurosurgery for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Experimental models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Lesions of Central Norepinephrine Terminals with 6-OH-Dopamine: Biochemistry and Fine Structure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Does levodopa accelerate Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mechanism of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Nitric oxide in the pathogenesis of vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Tetrahydrobiopterin regulates superoxide and nitric oxide generation by recombinant endothelial nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The effect of deprenyl (selegiline) on the natural history of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential i

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

MPTP toxicity in the mouse brain and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Nigrostriatal function in vitamin E deficiency: clinical, experimental, and positron emission tomographic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Alpha-tocopherol levels in brain are not altered in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mitochondrial complex I deficiency in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The effect of estrogen replacement on early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The Impact of Gender and Estrogen on Striatal Dopaminergic Neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Creatine monohydrate increases strength in patients with neuromuscular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Creatine and cyclocreatine attenuate MPTP neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Methamphetamine generates peroxynitrite and produces dopaminergic neurotoxicity in mice: protective effects of peroxynitrite decomposition catalyst

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Ebselen: prospective therapy for cerebral ischaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The antioxidant ebselen prevents neurotoxicity and clinical symptoms in a primate model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Novel free radical spin traps protect against malonate and MPTP neurotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Treatment with the spin-trap agent alpha-phenyl-N-tert-butyl nitrone does not enhance the survival of embryonic or adult dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Tissue distribution and neuroprotective effects of citrus flavonoid tangeretin in a rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Chronic administration of pharmacological levels of melatonin does not ameliorate the MPTP-induced degeneration of the nigrostriatal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Dose-dependent protective effects of apomorphine against methamphetamine-induced nigrostriatal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Toxic effects of apomorphine on rat cultured neurons and glial C6 cells, and protection with antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

SKF-38393, a dopamine receptor agonist, attenuates 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Neuroprotective effects of pramipexole in young and aged MPTP-treated mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Glutamine repeats and neurodegenerative diseases: molecular aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mechanisms of neurodegenerative disorders: Part 1: protein aggregates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mechanisms of neurodegenerative disorders: Part 2: control of cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Trial of d-alpha-tocopherol in Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Replicating Huntington's disease phenotype in experimental animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

3-nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Ketone bodies, potential therapeutic uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Taurine increases rat survival and reduces striatal damage caused by 3-nitropropionic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The antioxidant action of taurine, hypotaurine and their metabolic precursors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Tauroursodeoxycholic acid partially prevents apoptosis induced by 3-nitropropionic acid: evidence for a mitochondrial pathway independent of the permeability transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Recent advances in amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

What transgenic mice tell us about neurodegenerative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Formation of high molecular weight complexes of mutant Cu, Zn-superoxide dismutase in a mouse model for familial amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Extension of Drosophila lifespan by overexpression of human SOD1 in motorneurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Increases in cortical glutamate concentrations in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Blood-brain barrier permeation: molecular parameters governing passive diffusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Cytoprotective antioxidant function of tyrosine and tryptophan residues in transmembrane proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Association of vitamin E and C supplement use with cognitive function and dementia in elderly men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Nutritional factors in cerebral aging and dementia: epidemiological arguments for a role of oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Neurobehavioral aspects of antioxidants in aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Positron emission tomographic evidence for progression of human MPTP-induced dopaminergic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Neurological sequelae of cyanide intoxication--the patterns of clinical, magnetic resonance imaging, and positron emission tomography findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Progression after chronic manganese exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Traumatic brain injury as a risk factor for Alzheimer's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

A one-hit model of cell death in inherited neuronal degenerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Inherited neurodegenerative diseases: the one-hit model of neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Electrophile and antioxidant regulation of enzymes that detoxify carcinogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

The electrophile counterattack response: protection against neoplasia and toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

What do animal cancer tests tell us about human cancer risk?: Overview of analyses of the carcinogenic potency database

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Compounds that induce isoforms of glutathione S-transferase with properties of a critical enzyme in defense against oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Protein-bound acrolein: a novel marker of oxidative stress in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Dietary ortho phenols that induce glutathione S-transferase and increase the resistance of cells to hydrogen peroxide are potential cancer chemopreventives that act by two mechanisms: the alleviation of oxidative stress and the detoxification of mut

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Human glutathione transferase A4-4: an alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Apoptosis and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Apoptosis in neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Cancer chemoprevention and apoptosis mechanisms induced by dietary polyphenolics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Recent trends in glutathione biochemistry--glutathione-protein interactions: a molecular link between oxidative stress and cell proliferation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Oxidative stress and Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

L-cysteine, a bicarbonate-sensitive endogenous excitotoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Cytokine-stimulated, but not HIV-infected, human monocyte-derived macrophages produce neurotoxic levels of l -cysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Familial Aggregation of Parkinson's Disease in Iceland

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1407

10.1517/13543784.11.10.1407

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference